Business Context and Reporting Period
This Form 8-K, dated May 31, 2026, reports that Rallybio Corporation (RLYB) entered into a definitive Merger Agreement with Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company. Under the agreement, a wholly-owned subsidiary of Rallybio will merge with Avenzo, with Avenzo surviving as a wholly-owned subsidiary of Rallybio. The transaction is structured as a tax-free reorganization and involves a concurrent financing, a reverse stock split of Rallybio stock, and a name change to "Avenzo Therapeutics, Inc."
Key Financial Metrics and Transaction Structure
- Valuation Assumptions: The transaction is based on a pro forma valuation of $15.0 million for Rallybio (assuming no net cash) and $300.0 million for Avenzo.
- Concurrent Financing: Avenzo agreed to raise $215.0 million in gross proceeds from accredited investors immediately prior to the closing.
- Pro Forma Ownership (Fully Diluted):
- Avenzo pre-Merger equityholders: Approximately 56.6%
- Concurrent Financing Investors: Approximately 40.6%
- Rallybio pre-Merger equityholders: Approximately 2.8%
- Termination Fees:
- Avenzo to Rallybio: $20.0 million in specific scenarios (e.g., board recommendation change, breach, or alternative transaction within 12 months); $8.0 million if the deal fails to close by the End Date and an alternative transaction occurs within 12 months.
- Rallybio to Avenzo: $600,000 in specific scenarios (e.g., failure to close, breach, or board recommendation change).
- Expense Reimbursement: Each party agreed to reimburse the other up to $750,000 for third-party expenses upon termination in certain circumstances.
Material Changes and Operational Impact
The filing details a fundamental change in control and corporate structure. Upon closing, the current Rallybio executive officers and directors are expected to tender their resignations. The combined company's leadership will be led by Avenzo's management team, including Athena Countouriotis, M.D. (Chair, President, and CEO). The board of directors will consist of seven members initially designated by the Company. Rallybio will declare distributions of its net cash to shareholders prior to closing to ensure the company enters the merger with minimal cash, subject to a floor of $500,000 below zero net cash.
Guidance, Risks, and Contingencies
- Contingent Value Rights (CVRs): Rallybio shareholders will receive CVRs for each share held. These rights entitle holders to a pro rata share of net proceeds from the disposition of Rallybio's "Legacy Assets" or payments from Recursion Pharmaceuticals, Inc. There is no assurance that any payments will be made, and CVRs have no voting or dividend rights.
- Closing Conditions: The merger is subject to stockholder approval from both companies, Nasdaq listing approvals, effectiveness of the Form S-4, receipt of the $215.0 million financing, and the absence of material adverse effects.
- Support and Lock-Up Agreements: Rallybio insiders holding ~24.3% of stock and Avenzo insiders holding ~78% of stock have entered support agreements to vote in favor of the merger. Avenzo insiders have also entered 180-day lock-up agreements.
- Risks: Key risks include failure to satisfy closing conditions, delays in consummation, inability to raise the concurrent financing, and the possibility that CVR holders receive no value.
Investor Verification Checklist
- Verify the final "Rallybio Net Cash" amount at closing, as this directly impacts the Exchange Ratio and final ownership percentages.
- Confirm the status of the $215.0 million Concurrent Financing and the identity of the Investors.
- Review the upcoming Form S-4 and Proxy Statement for detailed risk factors and the specific reverse stock split ratio.
- Assess the likelihood and timeline for the disposition of Rallybio's Legacy Assets to determine potential CVR value.
- Monitor the resignation of current Rallybio directors and the composition of the new seven-member board.